Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Trastuzumab deruxtecan
Related studies linked through entity extraction aliases.
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil
- Status
- TERMINATED
- Phase
- N/A
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
- Status
- RECRUITING
- Phase
- N/A
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
- Status
- RECRUITING
- Phase
- N/A
Basket Study for Oligo-metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
DESTINY Breast Respond HER2-low Europe
- Status
- RECRUITING
- Phase
- N/A
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
- Status
- RECRUITING
- Phase
- PHASE2
TRUDI: TDXD+Durva in HER2+/Low IBC
- Status
- RECRUITING
- Phase
- PHASE2
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
- Status
- TERMINATED
- Phase
- PHASE2
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2